Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.

doi:10.1158/1078-0432.CCR-11-0868

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2012

Takahashi Ryo, Hirata Haruhiko, Tachibana Isao, Shimosegawa Eku, Inoue Atsuo, Nagatomo Izumi, Takeda Yoshito, Kida Hiroshi, Goya Sho, Kijima Takashi, Yoshida Mitsuhiro, Kumagai Toru, Kumanogoh Atsushi, Okumura Meinoshin, Hatazawa Jun, Kawase Ichiro

Abstract excerpt

PURPOSE: Positron emission tomography (PET) with [(18)F]fluorodeoxyglucose (FDG) is increasingly used in early assessment of tumor response after chemotherapy. We investigated whether a change in [(18)F]FDG uptake at 2 days of gefitinib treatment predicts outcome in patients with lung adenocarcinoma. EXPERIMENTAL DESIGN: Twenty patients were enrolled. [(18)F]FDG-PET/computed tomographic (CT) scan was carried out...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Adenosquamous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorodeoxyglucose F18

Share to Gefitinib

Share to Multimodal Imaging

Share to Positron-Emission Tomography

Share to Quinazolines

Share to Radiopharmaceuticals

Share to Tomography, X-Ray Computed

Source

Open in PubMed

Identifiers

PMID: 22019513
DOI: 10.1158/1078-0432.CCR-11-0868

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.PMID 22019513Read ↗

Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.Semantic proximity Read ↗

Early 18F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.Semantic proximity Read ↗

Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.Semantic proximity Read ↗

Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study.Semantic proximity Read ↗

(18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.Semantic proximity Read ↗

Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.Semantic proximity Read ↗

Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.Semantic proximity Read ↗

Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment.Semantic proximity Read ↗

Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.Semantic proximity Read ↗

Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.Semantic proximity Read ↗

A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks.Semantic proximity Read ↗

Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.